close

Enter

Log in using OpenID

Measles, Mumps and Rubella (MMR) Vaccines Market Estimated to Record Highest CAGR by 2026

embed
Measles, mumps, and rubella are the three common contagious airborne diseases that are highly caused by virus transmitted by sneezing and coughing of the infected person, which could lead to serious complications or death among children.
Measles, Mumps and Rubella (MMR) Vaccines
Market To Register Unwavering Growth During in
Global by 2026
Measles, Mumps and Rubella (MMR) Vaccines Market, by Product Type
(Monovalent, and Combinational (Divalent, Trivalent, and Others)) and by End
Users (Hospitals, Healthcare Centers, and Others) and by Region - Global
Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018 – 2026
Measles, mumps, and rubella are the three common contagious airborne diseases that are highly caused
by virus transmitted by sneezing and coughing of the infected person, which could lead to serious
complications or death among children. Vaccines of these diseases are sold as attenuated viral vaccines,
manufactured in a lyophilised formulation, which requires reconstitution with water for injection
diluent and are available in two forms i.e. monovalent as well as combinational vaccines.
Combinational MMR vaccines comprises mixture of two or more viral strains. Click to Read More On
Measles, Mumps and Rubella (MMR) Vaccines Market.
These measles, mumps, and rubella vaccines are administered by subcutaneous injection to children as
well as adults. It is generally administered to children aged 1 year and second dosage can be
administered as early as one month after the first dose. According to CDC, two doses of measles,
mumps and rubella vaccine are 97% effective against measles and 88% effective against mumps. One
dose of measles, mumps, and rubella vaccine is 93% effective against measles, 78% effective against
mumps, and 97% effective against rubella.
Measles, Mumps, and Rubella Vaccine Market Drivers
Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and GAVI
Alliance to improve their vaccination programs, in order to reach the maximum population to offer
vaccines. In spite of several governmental initiatives, measles is a leading cause of death among young
children. Therefore, increasing success rate of vaccination programmes depends on government
initiatives of each country.
Get The PDF Brochure of This Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1496
Some organizations are focusing on initiative, in order to reduce the prevalence of these diseases. For
instance, GAVI Alliances has undertaken an initiative to provide vaccination in high-risk countries such
as Afghanistan, Chad, Ethiopia, the Democratic Republic of the Congo, Nigeria and Pakistan.
Similarly, in 2017, the Government of India launches Pan-India Measles-Rubella vaccination
campaign, under which children ages from 9 months to 15 years are vaccinated to reduce the incidence
of these disease in children. Such initiatives by various organizations and governments is expected to
aid in growth of the market. Furthermore, development of combinational vaccines could aid in reducing
cost and adverse effects by reducing the number of vaccination programme.
Key manufacturers in the measles, mumps, and rubella vaccine market are focusing on launching new
vaccines, in order to enhance their share in the market. According to Access to Medicine Foundation
index, 2017, vaccine market is dominated by four major players, collectively referred as 'big four':
GSK, Merck & Co., Inc., Pfizer, and Sanofi. Big four contribute to 80% of the global vaccine revenue.
Measles, Mumps, and Rubella Vaccine Market - Competitors
The major manufacturers with WHO prequalified measles, mumps, and rubella vaccines are
GlaxoSmithKline (Belgium), Merck & Co. Inc. (USA) and Serum Institute of India Ltd, among others.
The global measles, mumps, and rubella vaccines market is segment on the basis of geography into
North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. According to the Pan
American Health Organization (PAHO), 2017, measles and rubella have been eliminated from the
Americas region, however, the challenge lies in preventing the outbreak.
Ask For Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/1496
However, according to a report by CDC’s National Center for Immunization and Respiratory Diseases
(NCIRD), in 2014, the U.S. recorded 667 number of measles cases from 27 states, which was the
highest number of cases since measles elimination was documented in the U.S. in 2000. This states that
the vaccine programs were unsuccessful in preventing the outbreak of the disease.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran303   documents Email
Document
Category
Health and Medicine
Views
7
File Size
367 KB
Tags
measles
1/--pages
Report inappropriate content